低磷血症作为PICU中增强营养代谢不耐受的生物标志物:PEPaNIC随机对照试验的二次分析
本文为PEPaNIC随机对照试验(n=1440)的二次分析,评估重症患儿早期低磷血症是否与随机干预(早期肠外营养 vs 延迟1周肠外营养)存在统计学交互作用。第2天低磷血症与随机分组在新发感染风险(P=0.031)、活体PICU出院可能性(P=0.030)和活体脱离机械通气时间(P=0.025)上存在交互作用,早期肠外营养的伤害在低磷血症患者中更明显;填补缺失磷数据后结果相似,并额外显示90天死亡率的交互作用(P=0.038)。作者结论认为低磷血症可能识别出被早期肠外营养伤害更明显的危重患儿,作为代谢不耐受生物标志物需进一步研究。
要点
- PEPaNIC二次分析(n=1440)中,第2天低磷血症与随机分组交互作用于新发感染风险(P=0.031)、活体PICU出院可能性(P=0.030)和活体脱离机械通气时间(P=0.025)。
- 第2天低磷血症患者中,早期肠外营养的伤害比无低磷血症患者更明显;填补缺失磷数据后结果相似,并额外显示90天死亡率交互作用(P=0.038),低磷血症患者早期肠外营养死亡率更高。
- 第1天低磷血症与随机干预对所有研究结局均无交互作用。
- 有磷检测数据的患者中,第1天低磷血症发生率为19.9%(211/1060),第2天为27.5%(243/883)。
- 作者结论:低磷血症可能识别出被早期肠外营养伤害更明显的危重患儿,作为代谢不耐受生物标志物需进一步研究。
适用人群与场景
- PEPaNIC随机对照试验纳入的危重患儿(n=1440),分析对象为有磷检测数据的患儿(第1天1060例,第2天883例)。
诊断标准与关键阈值
- 低磷血症依据PICU第1天和第2天磷酸盐异常判定;第1天低磷血症发生率19.9%(211/1060),第2天27.5%(243/883)。
研究设计与关键结果
- 研究类型:PEPaNIC随机对照试验的二次分析,样本量n=1440,人群为危重患儿,干预为早期肠外营养补充不足的肠内营养 vs 延迟1周肠外营养。
- 第1天低磷血症与随机干预对所有研究结局均无交互作用。
- 第2天低磷血症与随机分组交互作用于新发感染风险(P=0.031)、活体PICU出院可能性(P=0.030)和活体脱离机械通气时间(P=0.025);早期肠外营养的伤害在低磷血症患者中比无低磷血症患者更明显。
- 填补缺失磷数据(第1天20.3%,第2天22.0%)后结果相似,并额外显示90天死亡率交互作用(P=0.038),低磷血症患者中早期肠外营养死亡率更高。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析;试验注册号ClinicalTrials.gov NCT01536275,注册于2012年2月。
- 局限:作者结论指出该生物标志物用途需进一步研究(requires further investigation)。
对床旁实践的改变
- 作者认为,低磷血症的出现可能识别出被早期肠外营养伤害更明显的危重患儿,为将其用作增强营养代谢不耐受的生物标志物提供了前景,但该用途需进一步研究。
指南或共识出处
- PEPaNIC随机对照试验(ClinicalTrials.gov NCT01536275)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The PEPaNIC RCT showed that early supplementation of insufficient enteral nutrition by parenteral nutrition (early-PN) worsened outcome of critically ill children as compared with withholding PN for 1 week (late-PN). The best timing to initiate nutritional support in the pediatric intensive care unit (PICU) remains unclear. In adults, declining phosphate levels may identify patients who are particularly harmed by early-PN. We therefore assessed whether early hypophosphatemia in critically ill children may indicate metabolic intolerance to nutrition.
METHODS: In this secondary analysis of the PEPaNIC RCT (n = 1440), we investigated whether development of hypophosphatemia statistically interacts with the randomized intervention for its impact on clinical outcome, adjusting for baseline risk factors. Outcomes of interest included the incidence of new infections and the duration of PICU dependency as primary endpoints, 90-day mortality as safety endpoint, and duration of mechanical ventilation and of hospital stay as secondary endpoints. Subsequently, the impact of early-PN vs. late-PN in patients with and without early hypophosphatemia was assessed. Analyses were performed for phosphate abnormalities on PICU day 1 and 2, with and without imputing 20.3% (day 1) or 22.0% (day 2) missing phosphate data.
RESULTS: Of patients with available phosphate measurements, 19.9% (211/1060) and 27.5% (243/883) developed hypophosphatemia on day 1 and day 2, respectively. Day 1 hypophosphatemia did not interact with the randomized intervention for any studied outcome. On day 2, hypophosphatemia interacted with randomization for risk of new infection (P = 0.031), likelihood of earlier live PICU discharge (P = 0.030), and time to live weaning from mechanical ventilation (P = 0.025). Harm by early-PN was more pronounced in patients with hypophosphatemia than in those without. Results after imputing missing phosphate data were similar, with an additional interaction for 90-day mortality (P = 0.038) revealing higher mortality with early-PN in patients with hypophosphatemia.
CONCLUSIONS: Development of hypophosphatemia may identify critically ill children who are particularly harmed by early-PN. This opens perspectives for its use as a biomarker of metabolic intolerance to enhanced nutrition, which requires further investigation.
TRIAL REGISTRATION: ClinicalTrials.gov NCT01536275, registered February 2012.
参考来源
- Vanhorebeek I, Umman Serin N, Güiza F, et al. Hypophosphatemia as a biomarker of metabolic intolerance to enhanced nutrition in the PICU: a secondary analysis of the PEPaNIC RCT. Crit Care. 2026. PMID: 41680910. doi:10.1186/s13054-026-05844-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。